Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Lei He und 15 weiteren Autor:innen. Beteiligte Einrichtung: College of Animal Science and Technology, Guangxi University, Nanning 530005, China. Hauptthemen laut MEDLINE: Single-Domain Antibodies, SARS-CoV-2, Spike Glycoprotein, Coronavirus, COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 96 Literaturangaben. Gefördert von: Science and Technology Planning Project of Guangdong Province, H2020 Health, Advance Research Program of South China High Level Biosafety Laboratory.
Abstract (Originalsprache)
The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evaded the efficacy of previously developed antibodies and vaccines, thus remaining a significant global public health threat. Therefore, it is imperative to develop additional antibodies that are capable of neutralizing emerging variants. Nanobodies, as the smallest functional single-domain antibodies, exhibit enhanced stability and penetration ability, enabling them to recognize numerous concealed epitopes that are inaccessible to conventional antibodies. Herein, we constructed an immune library based on the immunization of alpaca with the S1 subunit of the SARS-CoV-2 spike protein, from which two nanobodies, Nb1 and Nb2, were selected using phage display technology for further characterization. Both nanobodies, with the binding residues residing within the receptor-binding domain (RBD) region of the spike, exhibited high affinity toward the S1 subunit. Moreover, they displayed cross-neutralizing activity against both wild-type SARS-CoV-2 and 10 ο variants, including BA.1, BA.2, BA.3, BA.5, BA.2.75, BF.7, BQ.1, EG.5.1, XBB.1.5, and JN.1. Molecular modeling and dynamics simulations predicted that both nanobodies interacted with the viral RBD through their complementarity determining region 1 (CDR1) and CDR2. These two nanobodies are novel tools for the development of therapeutic and diagnostic countermeasures targeting SARS-CoV-2 variants and potentially emerging coronaviruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Animal Science and Technology, Guangxi University, Nanning 530005, China.
- China Animal Disease Control Center, Beijing 102618, China.
- Institute of Human Virology, Department of Pathogen Biology and Biosecurity, and Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou 51008…
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou…
- College of Veterinary Medicine, Shanxi Agricultural University, Taigu 030801, China.
ORCID-Profile: Yi-Ping Li
Förderung
- Science and Technology Planning Project of Guangdong Province
- H2020 Health
- Advance Research Program of South China High Level Biosafety Laboratory
Zitieren
APA
He, L., Wu, Q., Zhang, Z., Chen, L., Yu, K., Li, L., Jia, Q., Wang, Y., Ni, J., Wang, C., Li, Q., Zhai, X., Zhao, J., Liu, Y., Fan, R., & Li, Y. P. (2024). Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00165
Vancouver
He L, Wu Q, Zhang Z, Chen L, Yu K, Li L, et al. Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00165
BibTeX
@article{He2024,
author = {He, Lei and Wu, Qian and Zhang, Zhaoyong and Chen, Lingling and Yu, Kuai and Li, Leibin and Jia, Qiong and Wang, Yanqun and Ni, Jianqiang and Wang, Chuanbin and Li, Qi and Zhai, Xinyan and Zhao, Jincun and Liu, Yuliang and Fan, Ruiwen and Li, Yi-Ping},
title = {Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00165}
}
EUVIMED